S&P 500   3,347.35 (+0.59%)
DOW   27,367.24 (+0.61%)
QQQ   274.24 (+1.18%)
AAPL   455.22 (+3.40%)
MSFT   215.29 (+1.10%)
FB   264.95 (+6.35%)
GOOGL   1,504.19 (+1.70%)
AMZN   3,233.63 (+0.89%)
NVDA   453.05 (+0.35%)
CGC   17.85 (-7.08%)
BABA   264.26 (-0.25%)
TSLA   1,504.47 (+1.31%)
MU   48.97 (-4.07%)
GE   6.34 (-0.94%)
AMD   86.54 (+1.44%)
T   29.84 (-0.03%)
F   6.94 (-0.29%)
ACB   10.23 (-4.48%)
GILD   68.93 (-0.10%)
NFLX   508.36 (+1.24%)
DIS   131.18 (+2.80%)
BAC   25.44 (+0.20%)
BA   172.61 (-0.96%)
S&P 500   3,347.35 (+0.59%)
DOW   27,367.24 (+0.61%)
QQQ   274.24 (+1.18%)
AAPL   455.22 (+3.40%)
MSFT   215.29 (+1.10%)
FB   264.95 (+6.35%)
GOOGL   1,504.19 (+1.70%)
AMZN   3,233.63 (+0.89%)
NVDA   453.05 (+0.35%)
CGC   17.85 (-7.08%)
BABA   264.26 (-0.25%)
TSLA   1,504.47 (+1.31%)
MU   48.97 (-4.07%)
GE   6.34 (-0.94%)
AMD   86.54 (+1.44%)
T   29.84 (-0.03%)
F   6.94 (-0.29%)
ACB   10.23 (-4.48%)
GILD   68.93 (-0.10%)
NFLX   508.36 (+1.24%)
DIS   131.18 (+2.80%)
BAC   25.44 (+0.20%)
BA   172.61 (-0.96%)
S&P 500   3,347.35 (+0.59%)
DOW   27,367.24 (+0.61%)
QQQ   274.24 (+1.18%)
AAPL   455.22 (+3.40%)
MSFT   215.29 (+1.10%)
FB   264.95 (+6.35%)
GOOGL   1,504.19 (+1.70%)
AMZN   3,233.63 (+0.89%)
NVDA   453.05 (+0.35%)
CGC   17.85 (-7.08%)
BABA   264.26 (-0.25%)
TSLA   1,504.47 (+1.31%)
MU   48.97 (-4.07%)
GE   6.34 (-0.94%)
AMD   86.54 (+1.44%)
T   29.84 (-0.03%)
F   6.94 (-0.29%)
ACB   10.23 (-4.48%)
GILD   68.93 (-0.10%)
NFLX   508.36 (+1.24%)
DIS   131.18 (+2.80%)
BAC   25.44 (+0.20%)
BA   172.61 (-0.96%)
S&P 500   3,347.35 (+0.59%)
DOW   27,367.24 (+0.61%)
QQQ   274.24 (+1.18%)
AAPL   455.22 (+3.40%)
MSFT   215.29 (+1.10%)
FB   264.95 (+6.35%)
GOOGL   1,504.19 (+1.70%)
AMZN   3,233.63 (+0.89%)
NVDA   453.05 (+0.35%)
CGC   17.85 (-7.08%)
BABA   264.26 (-0.25%)
TSLA   1,504.47 (+1.31%)
MU   48.97 (-4.07%)
GE   6.34 (-0.94%)
AMD   86.54 (+1.44%)
T   29.84 (-0.03%)
F   6.94 (-0.29%)
ACB   10.23 (-4.48%)
GILD   68.93 (-0.10%)
NFLX   508.36 (+1.24%)
DIS   131.18 (+2.80%)
BAC   25.44 (+0.20%)
BA   172.61 (-0.96%)
Log in

NASDAQ:QTRXQuanterix Stock Price, Forecast & News

$35.41
+0.36 (+1.03 %)
(As of 08/6/2020 02:57 PM ET)
Add
Compare
Today's Range
$34.65
Now: $35.41
$36.29
50-Day Range
$26.30
MA: $28.47
$33.18
52-Week Range
$10.90
Now: $35.41
$35.76
Volume6,881 shs
Average Volume237,612 shs
Market Capitalization$1.00 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.81
Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Simoa HD-1 instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. It also develops SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include kits, such as beads, capture and detector reagents, enzyme reagents, and enzyme substrates to run tests; and consumables, such as proprietary Simoa disks, cuvettes, and disposable tips. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sell its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Lexington, Massachusetts.
Read More
Quanterix logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.09 out of 5 stars


Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:QTRX
CUSIPN/A
Phone617-301-9400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$56.73 million
Book Value$4.59 per share

Profitability

Net Income$-40,800,000.00

Miscellaneous

Employees177
Market Cap$1.00 billion
Next Earnings DateN/A
OptionableNot Optionable
$35.41
+0.36 (+1.03 %)
(As of 08/6/2020 02:57 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive QTRX News and Ratings via Email

Sign-up to receive the latest news and ratings for QTRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Quanterix (NASDAQ:QTRX) Frequently Asked Questions

How has Quanterix's stock been impacted by COVID-19 (Coronavirus)?

Quanterix's stock was trading at $18.51 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, QTRX shares have increased by 91.3% and is now trading at $35.41.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Quanterix?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quanterix in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Quanterix
.

What price target have analysts set for QTRX?

4 Wall Street analysts have issued twelve-month target prices for Quanterix's shares. Their forecasts range from $35.00 to $40.00. On average, they anticipate Quanterix's stock price to reach $37.00 in the next twelve months. This suggests a possible upside of 4.5% from the stock's current price.
View analysts' price targets for Quanterix
.

Has Quanterix been receiving favorable news coverage?

Press coverage about QTRX stock has trended somewhat positive this week, InfoTrie Sentiment reports. The research firm scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Quanterix earned a media sentiment score of 1.4 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days.
View the latest news about Quanterix
.

Are investors shorting Quanterix?

Quanterix saw a drop in short interest during the month of July. As of July 31st, there was short interest totaling 1,120,000 shares, a drop of 7.4% from the July 15th total of 1,210,000 shares. Based on an average trading volume of 178,700 shares, the days-to-cover ratio is currently 6.3 days. Currently, 5.8% of the shares of the stock are sold short.
View Quanterix's Current Options Chain
.

Who are some of Quanterix's key competitors?

What other stocks do shareholders of Quanterix own?

Who are Quanterix's key executives?

Quanterix's management team includes the following people:
  • Mr. E. Kevin Hrusovsky, Chairman, Pres & CEO (Age 58)
  • Dr. David R. Walt, Co-Founder, Chairman of Scientific Advisory Board & Director (Age 66)
  • Dr. David C. Duffy Ph.D., Sr. VP of R&D and CTO (Age 48)
  • Mr. Amol Chaubal, Chief Financial Officer (Age 43)
  • Mr. Bruce J. Bal, VP of Operations, Service & Quality (Age 60)

When did Quanterix IPO?

(QTRX) raised $50 million in an initial public offering (IPO) on Thursday, December 7th 2017. The company issued 3,300,000 shares at $14.00-$16.00 per share. J.P. Morga and Leerink Partners acted as the underwriters for the IPO and BTIG and Evercore ISI were co-managers.

What is Quanterix's stock symbol?

Quanterix trades on the NASDAQ under the ticker symbol "QTRX."

Who are Quanterix's major shareholders?

Quanterix's stock is owned by a number of retail and institutional investors. Top institutional investors include Frontier Capital Management Co. LLC (2.96%), Kornitzer Capital Management Inc. KS (0.94%), WINTON GROUP Ltd (0.32%), Moody Aldrich Partners LLC (0.29%), Cadence Capital Management LLC (0.18%) and Swiss National Bank (0.15%). Company insiders that own Quanterix stock include Amol Chaubal, David C Duffy, David R Walt, Dawn Mattoon, E Kevin Hrusovsky, Ernest Orticerio, John J Fry, John M Connolly, Joseph Driscoll, Marijn E Dekkers, Mark T Roskey and Martin D Madaus.
View institutional ownership trends for Quanterix
.

Which institutional investors are selling Quanterix stock?

QTRX stock was sold by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd, Kornitzer Capital Management Inc. KS, and UBS Group AG. Company insiders that have sold Quanterix company stock in the last year include Amol Chaubal, David C Duffy, Dawn Mattoon, E Kevin Hrusovsky, John J Fry, Marijn E Dekkers, Mark T Roskey, and Martin D Madaus.
View insider buying and selling activity for Quanterix
.

Which institutional investors are buying Quanterix stock?

QTRX stock was bought by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Moody Aldrich Partners LLC, Cadence Capital Management LLC, Valmark Advisers Inc., Monarch Partners Asset Management LLC, Swiss National Bank, SG Americas Securities LLC, and Focused Wealth Management Inc. Company insiders that have bought Quanterix stock in the last two years include David R Walt, and John M Connolly.
View insider buying and selling activity for Quanterix
.

How do I buy shares of Quanterix?

Shares of QTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Quanterix's stock price today?

One share of QTRX stock can currently be purchased for approximately $35.41.

How big of a company is Quanterix?

Quanterix has a market capitalization of $1.00 billion and generates $56.73 million in revenue each year. The company earns $-40,800,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. Quanterix employs 177 workers across the globe.

What is Quanterix's official website?

The official website for Quanterix is www.quanterix.com.

How can I contact Quanterix?

Quanterix's mailing address is 900 MIDDLESEX TURNPIKE, BILLERICA MA, 01821. The company can be reached via phone at 617-301-9400.

This page was last updated on 8/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.